应用雷泰TPS验算治疗计划剂量可行性研究  

The feasibility research of checking treatment plan by using Linatech treatment planning system

作　　者：唐慧敏[1] 陆妙珍[1] Tang Huimin Lu Miaozhen(Department of Radiation Oncology, Ningbo City Medical Treatment Center Lihuili Hospital, Ningbo 315000, China)

机构地区：[1]浙江宁波市医疗中心李惠利医院放疗科,315000

出　　处：《中华放射肿瘤学杂志》2017年第7期800-805,共6页Chinese Journal of Radiation Oncology

摘　　要：目的 评估应用雷泰TiGRT TPS独立验算患者治疗计划剂量以实现IMRT质量保证的可行性和准确性.方法 实验基于美国瓦里安Trilogy加速器,以LinaTech （雷泰医疗）公司的TiGRT TPS 作为剂量独立验算工具.首先根据AAPM TG-119号报告中模体数据和处方剂量的要求在瓦里安Eclipse TPS中设计模体计划,用电离室Famer 2571测量模体计划的点剂量,比较电离室测量值和不同TPS的计算值.其次选取瓦里安Eclipse TPS中已治疗的鼻咽癌患者6例、乳腺癌术后放疗患者8例,用TiGRT TPS对选取病例进行独立剂量验算并进行剂量比较和分析.结果 在TG-119几何模体验证中,原计划点剂量、验算计划点剂量与测量值基本一致.在病例计算中,原计划与验算计划在乳腺癌中的差异较小,在鼻咽癌中的差异相对较大.在中心层面剂量的γ通过率评估中,所有病例在3 mm/3%的标准下的γ通过率均在90%以上.乳腺癌病例的γ通过率分别为（97.6±1.56）%和（97.1±1.10）%,鼻咽癌的通过率相对较低,分别为（92.6±3.46）%和（93.5±3.12）%.结论 应用LinaTech TiGRT TPS进行剂量独立验算来实现调强放疗治疗保证的方法具备可行性,验证过程方便快捷,同时可基于患者解剖结构和DVH差异,更全面控制和提升放射治疗质量.Objective To assess the feasibility of ＂secondary check＂ by LinaTech TiGRT treatment planning systems.Methods Choosing the Linatech TiGRT treatment planning system,researched and developed by Linatech company,as the third-party check tools.First,using Linatech TPS for recomputing treatment plans for geometrical phantoms designed in TG-119 and patients.after computation,compared the point dose with the measured data of phantoms （Using chameber No.2571 to measure point dose） and original plans.Using PTW verisoft with a criteria of 3% dose difference and 5 mm distance to agreement to assess the dose distribution on center level.After then,you can assess the accuracy of treatment plans.Results Tiny volume changes were found in ROI,especially in small size phantoms orcuspidal regions.For comparing measured data with recomputed plans and original plans,the dose data were found basically identical in TG-119 phantoms.And for patients,the differences between recomputed plans and AAA original plans or AXB original plans were smaller in breast cancer,but they were even bigger innasopharynx cancer,all patient cases showed a gamma passing rate more than 90%.The gamma passing rate of AAA original plans and AXB original plans were 95.6% and 97.53% for breast cancer,and 94.67% and 96.83% for nasopharynx cancer.Conclusions The method of utilizing the LinaTech TiGRT treatment planning system as a third-party check tools to assess the accuracy of plans is feasible,and the validation process is convenient,but some functions still need to improve and the scope of differences still need more patient cases to determine.

关 键 词：治疗计划系统 调强放射疗法 质量保证 

分 类 号：R730.55[医药卫生—肿瘤]